Test Catalog

Test Id : QFEVR

Order This Test

Q Fever Antibody Screen with Titer Reflex, Serum

Download
Overview

Test Catalog

Useful For
Suggests clinical disorders or settings where the test may be helpful

Screening for exposure to Coxiella burnetii, the causative agent of Q fever

 

This test should not be used as a screening procedure for the general population.

Reflex Tests
Lists tests that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial tests.

Test Id Reporting Name Available Separately Always Performed
QFP Q Fever IgM/IgG, Titer, S No No

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

If the Q fever serology result is reactive, then Q fever antibody confirmation by indirect immunofluorescence will be performed at an additional charge.

 

For more information see Infective Endocarditis: Diagnostic Testing for Identification of Microbiological Etiology.

Method Name
A short description of the method used to perform the test

Enzyme-Linked Immunosorbent Assay (ELISA)

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Q Fever Ab Scrn w/ Titer Reflex, S

Aliases
Lists additional common names for a test, as an aid in searching

Coxiella burnetii

Febrile Agglutinins

OX-19 (Proteus OX-19 - Weil-Felix)

OX-2 (Proteus OX-2 - Weil-Felix)

OS-K (Proteus OX-K - Weil-Felix)

Proteus (Weil-Felix)

Rickettsial Antibody

Typhus

Weil-Felix

QFEVR

Q-Fever

QFP

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

If the Q fever serology result is reactive, then Q fever antibody confirmation by indirect immunofluorescence will be performed at an additional charge.

 

For more information see Infective Endocarditis: Diagnostic Testing for Identification of Microbiological Etiology.

Specimen Type
Describes the specimen type validated for testing

Serum

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.6 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.

Special Instructions
Library of PDFs including pertinent information and forms related to the test

Forms

If not ordering electronically, complete, print, and send an Infectious Disease Serology Test Request (T916) with the specimen.

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.

0.5 mL

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject
Heat-inactivated specimen Reject

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 7 days
Frozen 7 days

Useful For
Suggests clinical disorders or settings where the test may be helpful

Screening for exposure to Coxiella burnetii, the causative agent of Q fever

 

This test should not be used as a screening procedure for the general population.

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

If the Q fever serology result is reactive, then Q fever antibody confirmation by indirect immunofluorescence will be performed at an additional charge.

 

For more information see Infective Endocarditis: Diagnostic Testing for Identification of Microbiological Etiology.

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Q fever, a rickettsial infection caused by Coxiella burnetii, has been recognized as a widely distributed zoonosis with the potential for causing both sporadic and epidemic disease. The resistance of C burnetii to heat, chemical agents, and desiccation allows the agent to survive for extended periods outside the host.

 

C burnetii is spread by the inhalation of infected material, largely from dried sheep and goat reproductive material; the organism is also shed in feces, milk, nasal discharge, placental tissue, and amniotic fluid from ruminant animals.

 

The clinical spectrum of disease ranges from unapparent to fatal. Respiratory manifestations usually predominate; endocarditis and hepatitis can be complications.

 

During the course of the infection, the outer membrane of the organism undergoes changes in its lipopolysaccharide structure, called phase variation. Differences in the host antibody response between phase I and phase II antigens can help classify infections as either acute or chronic:

-In acute Q fever, the phase II antibody is generally higher than the phase I titer, often by 4-fold, even in early specimens. Although a rise in phase I as well as phase II titers may occur in later specimens, the phase II titer remains higher.

-In chronic Q fever, the reverse situation is generally seen. Serum specimens collected late in the illness from chronic Q fever patients demonstrate significantly higher phase I titers, sometimes much greater than 4-fold.

-In the case of chronic granulomatous hepatitis, IgG and IgM titers to phase I and phase II antigens are quite elevated, with phase II titers generally equal to or greater than phase I titers.

-Titers seen in Q fever endocarditis are similar in magnitude, although the phase I titers are quite often higher than the phase II titers.

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Negative

Reference values apply to all ages

Interpretation
Provides information to assist in interpretation of the test results

Negative:

No antibodies to Q fever (Coxiella burnetii) detected. Repeat testing on a new sample collected in 2 to 3 weeks if acute Q fever is suspected.

 

Reactive:

Not diagnostic. Sample reflexed to the indirect immunofluorescence assay to determine Q fever (Coxiella burnetii) phase I and phase II IgM and IgG titers.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Serologic responses are time dependent. Specimens collected too early in the disease may not have detectable antibody levels. A second specimen collected 2 to 3 weeks may be necessary to detect antibody.

 

Cross-reactivity may occur with other closely related intracellular organisms (eg, Rickettsia species).

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Hartzell JD, Marrie TJ, Raoult D. Coxiella burnetii (Q fever). In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020:2360-2367

2. Anderson A, Bijlmer H, Fournier PE, et al. Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group [published correction appears in MMWR Recomm Rep. 2013 Sep 6;62(35):730]. MMWR Recomm Rep. 2013;62(RR-03):1-30

Method Description
Describes how the test is performed and provides a method-specific reference

The test uses microplate strips, each with 8 break-off reagent wells coated with purified native antigens from Coxiella burnetii cells in the acute and chronic phase. In the first reaction step, diluted samples are incubated in the wells. In the case of positive samples, specific IgA, IgG, or IgM antibodies will bind to the antigens. To detect the bound antibodies, a second incubation is carried out using an enzyme-labelled anti-human IgA-G-M (enzyme conjugate) catalyzing a color reaction.(Unpublished Mayo method)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Sunday through Friday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

1 to 4 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

14 days

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees :
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their account representative. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

86638

86638 x 4 (if applicable)

LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
QFEVR Q Fever Ab Scrn w/ Titer Reflex, S 23019-3
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
QFEVR Q Fever Ab Scrn w/ Titer Reflex, S 23019-3

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports

Test Update Resources

Change Type Effective Date
Test Status - Test Resumed 2024-02-28
Test Status - Test Delay 2024-02-21
Test Changes - Title 2023-08-17
New Test 2023-03-23